GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » Margin of Safety % (DCF FCF Based)

APRE (Aprea Therapeutics) Margin of Safety % (DCF FCF Based) : N/A (As of Dec. 11, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Aprea Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.


Competitive Comparison of Aprea Therapeutics's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Aprea Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprea Therapeutics's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Aprea Therapeutics's Margin of Safety % (DCF FCF Based) falls into.



Aprea Therapeutics Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Aprea Therapeutics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprea Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Executives
Oren Gilad officer: President, CEO 535 BOYLSTON STREET, BOSTON MA 02116
Marc Duey director 27 STRATHMORE ROAD, NATICK MA 01760
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
John P. Hamill officer: SrVP/CFO/Prin. Fin &Acctg. Off 4092 NEW HOPE ROAD, FURLONG PA 18925
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Grissinger director C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Rifat Pamukcu director 535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade director, officer: President & CEO MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar officer: SVP, Chief Medical Officer 535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel officer: Chief Business Officer 535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen officer: SVP, Chief Scientific Officer 535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129